View Press Releases
-
Rho to Coordinate NIAID COVID‐19 Vaccine Study in Autoimmune Disease Non‐Responders
Rho , a full-service contract research organization (CRO) with a proven track record of drug development success, today announced that it will be the Statistical and Clinical Coordinating Center for the COVID-19 Vaccine in Autoimmune Disease Non-Responders study. This clinical trial will assess the antibody response to an extra dose of an authorized or approved COVID-19 vaccine in people with autoimmune diseases who did not respond to an original COVID-19 vaccine regimen. The trial also will investigate whether pausing immunosuppressive therapy for autoimmune diseases improves the antibody response to an extra dose of a COVID-19 vaccine in this population. The Phase 2 trial is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and is being conducted by the NIAID-funded Autoimmunity Centers of Excellence.
Oct 31, 2021
-
CD Formulation Offers Multiple Methods for Microbial Limit Test
-
LIQUID STABLE & READY-TO-USE TOTAL PROTEIN / ALBUMIN CLINICAL REFERENCE MATERIALS AVAILABLE FROM VERICHEM LABORATORIES
An extensive offering of liquid stable and ready-to-use combined Total Protein/Albumin clinical reference materials are now available from VERICHEM specifically designed and manufactured for the calibration and calibration verification of the analytes on a large number of clinical testing systems,
Nov 1, 2021
-
PreOmics launches BeatBox at ASMS 2021 for high throughput tissue homogenization
Introducing BeatBox: PreOmics launches its new sample preparation tool for tissues and cells
Oct 31, 2021
-
Emmes launches Orphan Reach™: Emmes’ Rare Disease Center
The new global Rare Disease center of Emmes expects accelerating growth from US and European biotechs
Nov 2, 2021
-
Panthera@theRutherford clinical trial partnership has commenced the first UK multicentre oncology trial in prostate cancer with ten more oncology trials in the pipeline
The first multisite oncology trial undertaken by the independent sector in the UK has started treating its first patient at the Rutherford Cancer Centre North East.
Nov 1, 2021
-
Gundersen Health System Partners with Kyruus to Propel Digital Access Transformation
Innovative Wisconsin-Based Healthcare Network Deploying Kyruus ProviderMatch® Platform to Modernize How Consumers Find Providers Online
Nov 2, 2021
-
2bPrecise Joins the Epic App Orchard to Bring Its Precision Medicine Insights to the Point of Care
2bPrecise™ announced its Precision Health™ platform is now available in the Epic App Orchard Gallery.
Nov 2, 2021
-
Exclusive interview with Professor Sir John Bell announced as Life Science Integrates celebrates ten years of Pharma Integrates
Life Science Integrates (LSI) is delighted to announce the exciting agenda for its flagship event, Pharma Integrates, held live online on 16th November 2021.
Nov 2, 2021
-
Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better
Curebase, LEVEL Announce Clinical Trial to Determine Whether Cannabinoids Can Help Veterans Sleep Better
Nov 2, 2021
-
Swiss CDMO Invests in Powder Containment and Extends Spray Drying Capabilities
-
Aragen expects to ride wave of US biotech growth in 2022 – influx of discovery capital is surging demand for CDMO services
Company plans wide ranging investments and expansions to keep pace with demand driven by macro-changes and diversifying client base
Nov 4, 2021
-
Qlucore approved for listing on Nasdaq First North Growth Market
Qlucore AB (public) (“Qlucore” or “Company”) has today received approval of the application for listing of Qlucore shares on the Nasdaq First North Growth Market. The first day of trading of the shares will be 5th November 2021. Trading will be done with the ticker QCORE.
Nov 4, 2021
-
CMOs will account for four of the five top bio manufacturing capacities in 2025
230 Covid-19 supply agreements known, with demand for larger biocapacity remaining constrained as a consequence of the circa 1000 vaccines in development
Nov 4, 2021
-
Pillar VC and Petri Announce Winners of $200K Pitch Competition
Pillar VC and Petri have announced the winners of the $200K Pitch Competition that took place during the Founder-Led Biotech Summit, a free virtual event that brought together biotech founders, faculty, PhDs, scientists, investors, and executives to support the founder-led biotech movement.
Nov 7, 2021
-
The Community Blood Center (Appleton, WI) to roll out biolog-id’s technology to support platelet lifecycle management
The Community Blood Center is the latest regional blood center to embrace biolog-id’s technology. Biolog-id’s solution for platelet lifecycle management will be deployed to support the efficiency of platelet manufacturing, documentation, and inventory management.
Nov 7, 2021
-
Birmingham Biotech and the University of Birmingham sign licensing agreement for anti-viral nasal spray against COVID-19
Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.
Nov 8, 2021
-
CHARGEPOINT TECHNOLOGY APPOINTS NEW COO TO DRIVE FUTURE GROWTH
-
Protheragen MedAI Upgrades CADD Platform to Accelerate Drug Design
-
Samsung Biologics Reports Strong Second Quarter 2021 Financial Results